Lanean...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Martinelli, Giovanni, Iacobucci, Ilaria, Soverini, Simona, Palandri, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Baccarani, Michele
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2007
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721303/
https://ncbi.nlm.nih.gov/pubmed/19707322
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!